Retatrutide

Main evidence: Human clinical trials. Updated 2026-10-28.

What research and users report, not a recommendation or medical advice. Many of these products are not approved for human use. Ask your doctor. Packs report what sources say, each with its evidence label. A claim labelled community, educator, manufacturer or animal has not been validated in humans.

Summary

This pack summarizes trial evidence, safety information and Australian regulatory context for investigational retatrutide.

What the sources say

No combination benefit or safety is established in the cited human trial publications; those studies do not test retatrutide combined with another peptide. (Human clinical trials; Jastreboff AM et al., "Retatrutide for Treatment of Obesity (TRIUMPH-1)", 2026-09-29)
Retatrutide is an investigational peptide agonist at GIP, GLP-1 and glucagon receptors. Published obesity trials used once-weekly subcutaneous administration; this describes research, not an approved product or personal-use protocol. (Human clinical trials; Jastreboff AM et al., "Triple-Hormone-Receptor Agonist Retatrutide for Obesity: A Phase 2 Trial", 2023-06-26)
Online community posts describe appetite reduction, weight change, energy or sleep changes, as well as gastrointestinal symptoms and skin sensitivity. Self-reports cannot verify vial identity, dose, route, adherence or causation. (Community reports; r/NTNPerformance, "Retatrutide breakdown, what it is and how the dose ladder works", 2026-08-28)
The cited trials report gastrointestinal effects and dose-related heart-rate changes; these are group-level trial findings and do not predict an individual response. (Human clinical trials; Jastreboff AM et al., "Retatrutide for Treatment of Obesity (TRIUMPH-1)", 2026-09-29)
The TGA reported a serious Australian event involving a product sold as retatrutide: testing found no retatrutide and about 8 times the amount of semaglutide found in TGA-assessed products; the consumer experienced uncontrollable vomiting and a torn oesophagus. This single case does not establish counterfeit-product prevalence. (Educator material (not peer reviewed); TGA, "TGA tests counterfeit retatrutide product following serious adverse event report", 2026-09-14)
The TGA and Chief Medical Officer warn that unapproved peptide products may have uncertain identity, composition, sterility and dosing, and associate unapproved products generally with liver injury, severe allergic reactions and inflammation; these are class-level warnings, not retatrutide-specific event rates. (Educator material (not peer reviewed); TGA and Chief Medical Officer, "Concerns regarding the public health risks associated with unapproved peptide products", 2026-06-19)
As of 2026-10-28, the TGA/Chief Medical Officer warning names retatrutide among unapproved peptide products and says such products have not been assessed for safety, quality or effectiveness in Australia; the notice strongly advises Australians not to purchase or use them, particularly from online or overseas sources. (Educator material (not peer reviewed); TGA and Chief Medical Officer, "Concerns regarding the public health risks associated with unapproved peptide products", 2026-06-19)
TGA guidance describes supply and advertising restrictions for unapproved therapeutic goods unless an exemption applies. This draft does not make a categorical claim about every possession, importation or individual circumstance; legal status is fact-specific and time-sensitive. (Educator material (not peer reviewed); TGA and Chief Medical Officer, "Concerns regarding the public health risks associated with unapproved peptide products", 2026-06-19)

Sources

Dosing, stacking and protocol details are not published here.